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Asp9-Asn (exon 2) and Asn291-Ser (exon 6), in decreased LPL activity and reduced 
HDL-C levels amongst patients with familial combined hyperlipidaemia. We investigated 
the potential influence of these mutations upon serum lipids/lipoproteins amongst the 
representative, homogeneous, adult male population of Caerphilly. 
Methods: 2,316 men were purposely recruited into the Caerphilly Prospective Heart Dis- 
ease Study, when they were aged between 45-59 years, to prospectively screen and 
monitor them for CHD and its risk factors. DNA was available for genotyping on 1,958 
men from the phase 2 collection. We genotype d them for these mutations and the data 
was assessed using non-parametric statistical analyses. 
Results: The T2 (Asp9-Asn) and R2 (Asn291-Ser) alleles denote restriction sites for the 
Taql and Rsal enzymes, respectively. Men possessing the T1 allele had significantly 
raised levels of apo-A1 (131.3 mg/dl vs 124.9 mg/dl, p=0.009), the major surface protein 
activating HDL. Whilst individuals possessing the R2 allele had significantly reduced 
HDL-C levels (0.90 mmol/I vs 1.02 mmol/1, p--O.006) and increased TC/HDL-C ratios 
(6.73 vs 5.84, p=0.043). Interestingly, our cohort did not have any R2R2 homozygotes. 
Conclusions: Our data suggests that the LPL gene influences lipids/ lipoproteins and 
dyslipideemia mongst he UK adult, male population. 
1083-70 Modulation by TGF-Betel  of  Oxldlzed-LDL-Induced 
Upregulat lon of P-Selectln and IGAM-1 and Monocyte 
Adhesion in Human Coronary Endothelial Cells 
Jawahar L. Mehta, Honoiiano Chen, Dayuan Li, University of Arkansas for Medical 
Sciences, Little Rock, Arkansas, Central Arkansas Veterans Healthcare System, Little 
Rock, Arkansas. 
Background: Oxidized-LDL (ox-LDL) upregulates expression of LOX-1, a specialized lec- 
tin-like receptor, on endothelial cells. Uprsgulation of LOX-1 is associated with expression 
of adhesion molecules and monocyte adhesion to endothelial cells. This mechanism may 
relate to the pathogenicity of ox-LDL in atherogenesis. Further, TGF-betal has been postu- 
lated to exert tissue protective and anti-atherogenic effect. We designed this study to inves- 
tigate the role of TGF-betal in ox-LDL-induced expression of adhesion molecules and 
monocyte adhesion to human coronary artery endothelial cells (HCAECs). 
Methods and results: Fifth generation cultured HCAECs were incubated with native-LDL or 
ox-LDL (10-40 mg/ml) for 1-24 hrs. Parallel sets of HCAECs were treated with a specific 
antibody to LOX-1 (10 mg/ml) or to recombinant TGF-betal (2 ng/ml) before incubation 
with ox-LDL (40 mg/ml). Incubation of HCAECs with ox-LDL, but not native-LDL, signifi- 
cantly increased expression P-selectin and ICAM-1 (Western analysis) and monocyte 
adhesion to HCAECs (all P<0.01 vs. n-LDL, n=5). Ox-LDL also decreased active TGF- 
bets1 levels (measured by ELISA) in a time- and concentration-dependent manner 
(P<0.05 vs. control). Antibody to LOX-1 attenuated the reduction in TGF-betal levels 
(P<0.05 vs. ox-LDL alone). Simultaneously, recombinant TGF-betal reduced the expres- 
sion of P-selectin and ICAM-1, as well as monocyte adhesion to HCAECs induced by ox- 
LDL (all P<0.02, n=5). 
Conclusion: This study shows that 1) ox-LDL decreases active TGF-betal levels by activa- 
tion of LOX-1; 2) the reduction in active TGF-betal may be the basis of ox-LDL-mediated 
upregulation of P-selsctin and ICAM-1 expression and monocyte adhesion to HCAECs. 
1083-71 A Cholesteryl Ester Transfer Protein Inhibitor Increased 
In Vlvo Synthatlc Rates and Liver mRNA Levels of 
Apol lpoprofein A-I 
Eiso Shimoji, Bo Zhano, Ping Fan, Keijiro Saku, Fukuoka Universi~ Fukuoka, Japan. 
Background: Patients with cholesteryl ester transfer protein (CETP) deficiency have 
increased HDL-C levels, and the inhibition of CETP activity has been shown to increase 
apolipoprotein (ape) A-I levels and suppress the progression of atheroosclerosis n choles- 
terol-fed rabbits. To clarify the mechanism by which CETP inhibition increases serum apo 
A-I levels, the effects of a CETP inhibitor, JTT-705, on in vivo apo A°I kinetics and tissue 
apo A-I gene expression were investigated. 
Methods: Japanese White rabbits were randomly fed a diet with (n=8, treated) or without 
(n=10, controls) 0.75% J'l-r-705 (Japan Tabasco Inc.) for 7 mo. CETP activities and 
serum levels of apo A-I and HDL-C levels were measured. Apo A-I kinetics were per- 
formed by injecting radioiodinated apo A-I, which was freshly prepared by the guanidine 
HCI method. Apo A-I mRNA levels in the liver and intestine were quantified by SYBR 
real-time RT-PCR. 
Results: JTT-705 inhibited 32.0% of the CETP activity and increased (p<0.05) the serum 
levels of HDL-C and apo A-I (66.5 ± 13.7 vs. 42.9 ± 6.2 mg/dL). Treated rabbits had a 
greater (p<O.05) synthetic rate (SR) of HDL-apo A-I than control rabbits (13.1 ± 2.6 vs. 
10.0 ± 1.9 mg/Kg/day), while the fractional catabolic rates in the two groups were similar 
(0.47 ± 0.10/day and 0.52 ± 0.09/day). JTT-705 increased apo A-I mRNA levels In the 
liver but not In Inteetlne (Figure). 
Conclusion: Increased SR and liver gene expression of apo A-I contribute to the 
increased serum apo A-I levels induced by CETP inhibition. 
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1083-95 Mutation In the Promoter Region of the Hepatic Lipase 
Gene Correlates With Dysl ipidemia In Type 2 Diabetes 
RaJ K. Mattu. Edward W. Needham, Jasper Trevelyan, Dimitri J. Richter, Maria A. 
Adiseshiah, Mauro Lencioni, Shane Gieewarsingh, D. John Befferidge, University 
Hospitals Coventry & Warwickshire &University of Warwick, Coventry, United Kingdom, 
University College London Medical School, London, United Kingdom. 
Background: Cardiovascular disease remains the major cause of morbidity and mortality 
amongst ype II diabetics. The total coronary heart disease risk of these patients is much 
higher than for non-diabetics at every level of given risk factor, such as dyslipidaemia. 
About 40% of diabetics have hypertriglyceridaemia (HTG) and reduced high-density Iipo- 
protein cholesterol (HDL-C). Hepatic lipase (HL) is a key enzyme in the hydrolysis of trig- 
lycerides in the core of remnant lipoprotein particles and facilitates activation of HDL 
particles. It therefore influences serum triglycedde and HDL-C levels and may be an 
important determinant of the dyslipidaemia observed amongst diabetics. A C-514-T 
mutation involving the promoter egion of the HL gene associates with reduced HL activ- 
ity and increased HDL2 levels, hence we examined whether this mutation related 10 
serum lipids amongst ype II diabetics. 
Methods: We recruited 386 consecutive patients attending the diabetes clinic. All cardio- 
vascular risk factors were characterised and studied once the patient's diabetic control 
had become satisfactory. Patient lipids were analysed without lipid modifying drugs. 
Patients were genotyped using the polymerase chain reaction. 
Results: Triglyceride levels were significantly higher (3.25 vs 2.53 retool/I, p=0.03) 
amongst diabetics possessing the TT genofype. Furthermore, subjects possessing the 
C-514-T promoter mutation had a 78% increased risk of being in the highest tertile of the 
total cholesterol/HDL-C ratio distribution, O.R. 1.78 (1.00-3.17, p=0.048). 
Conclusions: Mutation of the promoter egion of the hepatic lipase gene may predispose 
type II diabetic patients to a deleterious lipid profile and possibly influence their coronary 
heart disease risk. 
1083-96 Increasing Testosterone Lowers High Density 
Lipoproteln Cholesterol by Decreasing Apol lpoproteins 
AI and All 
John A. Morrison, Dennis L. Sprscher, Bruce A. Barton, Children's Hospital Medical 
Center, Cincinnati, Ohio, Maryland Research Institute, Baltimore, Maryland. 
Background: During puberty, high density lipoprotein cholesterol (HDL-C) and its major 
associated apolipoproteins (apo), AI and All, decrease markedly in males, but not in 
females, resulting in the recognized sex differences in lipid profiles and attendant risk to 
coronary heart disease. The timing of the changes has implicated sex steroid hormones, 
especially free testosterone (T) in the changes. Previous studies of pubertal males have 
been limited by small samples, cross sectional designs, or longitudinal designs using 
only two points in time, design elements that restrict he power of the studies. 
Methods: To explicate the role of free T in the pubertal changes in adolescent male lipids 
we followed 251 black and 283 white males, ages 10-15 yrs at enrollment, for three 
years. We measured lipid profiles, free testosterone (T), estradiol, and body mass index 
(BMI = kg/m2) every 6 months and apo AI and All annually. 
Results: Controlling for pubertal stage, black males had higher HDL-C, apoAI, (all 
p<.001), and apoAII (p=.06) than white males. With advancing pubertal stage, HDL-C, 
apoAI and All decreased in both black and white boys. Longitudinal, multivariate analy- 
ses (General Estimating Equations) showed that increasing free T associated with 
decreasing HDL-C, apo AI and All (all p<.01), but did not affect the ratio of HDL-C to 
apoAI and All. When apoAI and All were entered into the model for changes in HDL-C as 
predictors, they contnbuted significantly to decreases in HDL-C. At this point, however, 
free T dropped out of the model, suggesting that the effects of free T on HDL-C are medi- 
ated through apoAI and All concentrations. Increasing BMI associated with lower HDL-C 
and HDL-C/(apoAI and All) ratios but did not associate with changes in apoAI. Estrediol 
was not associated with changes in HDL-C, apo AI or All. 
Conclusions: During puberty, increasing T appears to contribute to lower HDL-C by low- 
ering the apolipoproteins (apoAI and All) available to these particles, not by altering the 
amount of lipid associated with these protein moieties. 
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1084-90 Ezatimlbe Co-Administered With Slmvastatin in 668 
Patients With Primary Hyperch01esterolemia 
Michael Davidson, Thomas McGarry, Robed Battis, Lorenzo Melani, Leslie Lipka, 
Alexandre LeBeaut, Ramachandrsn Suresh, Steven Sun, Enrico Veltri, for the Ezetimibe 
Study Group, Chicago Center for Cardiovascular Research, Chicago, Illinois, Oklahoma 
Foundation for Clinical Research, Oklahoma Ci~ Oklahoma. 
Background: This Phase III, randomized, double-blind, placebo-controlled study evalu- 
ated the efficacy and safety of ezetimibe (EZE) administered with simvastatin (SIM) in pts 
with primary hyparcholesterolemia. 
Methods: After dietary stabilization (NCEP Step 1 or stricter diet), a 2-12 wk screening/ 
washout period and a 4-wk, single-blind, PBO lead-in period, 668 pts with baseline LDL- 
C _>145 mg/dl to -<250 rag/all and TG -<350 rag/all were randomized to 1 of the following 
administered aily for 12 consecutive wks: EZE 10 rag; SIM 10, 20, 40 or 80 rag; EZE mg 
